Tag Archives: Remicade biosimilar

Arthritis Biosimilar

FDA Approves Second Remicade biosimilar

The U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab), making it the fourth biosimilar approved to treat inflammatory types of arthritis.

Renflexis is the second approved biosimilar to Remicade. The first one, Inflectra (infliximab-dyyb), was approved in April 2016. This is the first time the FDA has approved two biosimilars for one original, “reference” medication.
Continue reading FDA Approves Second Remicade biosimilar

inflectra biosimilar injection

Inflectra, a Remicade Biosimilar, Now Available Through Medicare and Medicaid

Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), is now covered by Medicare and Medicaid. Approved by the Food and Drug Administration in April 2016, Inflectra is the first biosimilar indicated for the treatment of rheumatic and inflammatory diseases to come to market in the United States. The Centers for Medicare and Medicaid Services added it to its pricing list beginning January 1, 2017.

Continue reading Inflectra, a Remicade Biosimilar, Now Available Through Medicare and Medicaid

Akylosing Spodylitis Treatment

FDA Approves First Biosimilar for Arthritis

The U.S. Food and Drug Administration (FDA) has approved Inflectra – a so-called biosimilar version of the biologic Remicade (infliximab) – to treat rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) as well as psoriasis and inflammatory bowel disease. It is the first biosimilar approved in the U.S. for autoimmune, inflammatory conditions, including RA, PsA and AS, and only the second biosimilar approved by the agency to date. (A drug used in cancer treatment, filgrastim-sndz, sold as Zarxio, was approved in March 2015.)
Continue reading FDA Approves First Biosimilar for Arthritis

Akylosing Spodylitis Treatment

FDA Panel Endorses Remicade Biosimilar, a First for Arthritis

The Arthritis Advisory Committee to the Food and Drug Administration (FDA) voted 21 to 3 on Tuesday (Feb. 9) to recommend approval of CT-P13, a biosimilar version of Remicade (infliximab), which is used to treat inflammatory types of arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosking spondylitis (AS). CT-P13 is the first biosimilar to treat arthritis to reach this milestone.

Similar but not identical

A biosimilar is highly similar to, but not exactly the same as the existing, FDA-approved biologic, called the “reference” drug (in this case Remicade). People are familiar with generic versions of brand-name drugs, but biosimilars are not generic drugs. Generic versions of brand-name drugs are exact copies of chemically synthesized medicines. Biosimilars are not-quite-perfect copies of biologics – drugs derived from living cells that are impossible to replicate exactly.
Continue reading FDA Panel Endorses Remicade Biosimilar, a First for Arthritis